
OmniAb Inc (OABI) Stock Forecast & Price Target
OmniAb Inc (OABI) Analyst Ratings
Bulls say
OmniAb Inc has demonstrated a positive financial trajectory, reporting revenues of $4.2 million for 1Q25, which reflects a 9% increase year-over-year. The company has also reduced its net losses to $18.2 million, equivalent to ($0.17) per share, compared to a loss of $19.0 million or ($0.19) per share in the previous year. Anticipated near- and long-term research and development catalysts, combined with a solid balance sheet, position the company favorably for future growth.
Bears say
OmniAb Inc's stock has experienced a decline since its November 2022 merger with Avista Public Acquisition Corporation II, influenced by negative market trends affecting both similar mergers and established biotech companies. The company's guidance indicates an operating cash burn for the current year that is projected to be lower than that of 2024, which raises concerns about its cost management and financial sustainability in the near term. Overall, these factors contribute to a negative outlook regarding the company's stock performance amidst challenging market conditions.
This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.
OmniAb Inc (OABI) Analyst Forecast & Price Prediction
Start investing in OmniAb Inc (OABI)
Order type
Buy in
Order amount
Est. shares
0 shares